A1JTY

Bempedoic acid

Created:	2025-11-06
Last modified:	2025-12-17

Find Related PDB Entry
1 entries where A1JTY is found as a standalone ligand

Help Find related ligands:
Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Help

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	60
Chiral Atom Count	0
Bond Count	59
Aromatic Bond Count	0

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	Bempedoic acid
Synonyms	2,2,14,14-tetramethyl-8-oxidanyl-pentadecanedioic acid
Systematic Name (OpenEye OEToolkits)	2,2,14,14-tetramethyl-8-oxidanyl-pentadecanedioic acid
Formula	C₁₉ H₃₆ O₅
Molecular Weight	344.486
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
SMILES	OpenEye OEToolkits	2.0.7	CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
Canonical SMILES	CACTVS	3.385	CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O
Canonical SMILES	OpenEye OEToolkits	2.0.7	CC(C)(CCCCCC(CCCCCC(C)(C)C(=O)O)O)C(=O)O
InChI	InChI	1.06	InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
InChIKey	InChI	1.06	HYHMLYSLQUKXKP-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB11936
Name	Bempedoic acid
Groups	approved investigational
Description	High levels of LDL cholesterol (LDL-C) are a major risk factor for cardiovascular events. Caused by genetic mutations or lifestyle factors, hypercholesterolemia can significantly reduce quality of life and increase the risk of mortality from cardiovascular disease.[L12153] About 1 in 4 patients, or 15 million Americans with elevated LDL-C, are insufficiently managed with maximally tolerated statin therapy alone, requiring additional treatment for hypercholesterolemia.[L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients.[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020. A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous statin treatment.[L12144,L12150]
Synonyms	Bempedoic acid
Brand Names	Nustendi Nexlizet Nilemdo Nexletol
Indication	Bempedoic acid is indicated to reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy and have established cardiovascular disease or are at high risk of a cardiovascular event.[L50963] It is also indicated as an adjunct to diet, with or without other LDL-C lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH).[L50963] Bempedoic acid in combination with [ezetimibe] is also indicated for the same.[L50968]
Categories	Acids, Acyclic Adenosine Triphosphate-Citrate Lyase Inhibitor Adenosine Triphosphate-Citrate Lyase Inhibitors Enzyme Inhibitors Hypolipidemic Agents Hypolipidemic Agents Indicated for Hyperlipidemia Lipid Modifying Agents Lipid Modifying Agents, Plain Lipid Regulating Agents Non-statin Hypolipidemic Agents Indicated for Hyperlipidemia OATP1B1/SLCO1B1 Inhibitors OATP1B3 inhibitors OATP1B3 substrates UGT2B7 substrates
ATC-Code	C10AX15 C10BA10
CAS number	738606-46-7

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

Name	Target Sequence	Pharmacological Action	Actions
ATP-citrate synthase	MSAKAISEQTGKELLYKFICTTSAIQNRFKYARVTPDTDWARLLQDHPWL...	unknown	inhibitor
Long-chain fatty acid transport protein 2	MLSAIYTVLAGLLFLPLLVNLCCPYFFQDIGYFLKVAAVGRRVRSYGKRR...	unknown	substrate
UDP-glucuronosyltransferase 2B7	MSVKWTSVILLIQLSFCFSSGNCGKVLVWAAEYSHWMNIKTILDELIQRG...	unknown	substrate
NUAK family SNF1-like kinase 2	MESLVFARRSGPTPSAAELARPLAEGLIKSPKPLMKKQAVKRHHHKHNLR...	unknown	activator
Solute carrier organic anion transporter family member 1B1	MDQNQHLNKTAEAQPSENKKTRYCNGLKMFLAALSLSFIAKTLGAIIMKS...	unknown	inhibitor
ATP-binding cassette sub-family C member 3	MDALCGSGELGSKFWDSNLSVHTENPDLTPCFQNSLLAWVPCIYLWVALP...	unknown	inhibitor
Solute carrier organic anion transporter family member 1B3	MDQHQHLNKTAESASSEKKKTRRCNGFKMFLAALSFSYIAKALGGIIMKI...	unknown	substrate,inhibitor
View More

Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682